BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28474091)

  • 1. Cardiac intimal sarcoma with PDGFRβ mutation and co-amplification of PDGFRα and MDM2: an autopsy case analyzed by whole-exome sequencing.
    Ito Y; Maeda D; Yoshida M; Yoshida A; Kudo-Asabe Y; Nanjyo H; Izumi C; Yamamoto F; Inoue M; Shibata H; Katoh H; Ishikawa S; Nakamura H; Totoki Y; Shibata T; Yachida S; Goto A
    Virchows Arch; 2017 Sep; 471(3):423-428. PubMed ID: 28474091
    [No Abstract]   [Full Text] [Related]  

  • 2. MDM2 dual-color in situ hybridization (DISH) aids the diagnosis of intimal sarcomas.
    Jimbo N; Komatsu M; Itoh T; Hirose T
    Cardiovasc Pathol; 2019; 43():107142. PubMed ID: 31442826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary cardiac undifferentiated pleomorphic sarcoma is associated with TP53 mutation during lack of MDM2 amplification, and targeted sequencing analysis reveals potentially actionable targets.
    Cui Y; Han L; Shang J; Fang W; Zhao M; Chen D; Liu H
    Hum Pathol; 2022 May; 123():113-122. PubMed ID: 35181378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature.
    Koelsche C; Benhamida JK; Kommoss FKF; Stichel D; Jones DTW; Pfister SM; Heilig CE; Fröhling S; Stenzinger A; Buslei R; Mentzel T; Baumhoer D; Ladanyi M; Antonescu CR; Flucke U; Gorp JV; Bode-Lesniewska B; Deimling AV; Mechtersheimer G
    Mod Pathol; 2021 Dec; 34(12):2122-2129. PubMed ID: 34312479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary cardiac sarcomas: A clinicopathologic study in a single institution with 25 years of experience with an emphasis on MDM2 expression and adjuvant therapy for prognosis.
    Cho H; Song IH; Jo U; Jeong JS; Koo HJ; Yang DH; Jung SH; Song JS; Cho KJ
    Cancer Med; 2023 Aug; 12(16):16815-16828. PubMed ID: 37395142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas.
    Tamborini E; Casieri P; Miselli F; Orsenigo M; Negri T; Piacenza C; Stacchiotti S; Gronchi A; Pastorino U; Pierotti MA; Pilotti S
    J Pathol; 2007 Jun; 212(2):227-35. PubMed ID: 17471466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis.
    Ito M; Barys L; O'Reilly T; Young S; Gorbatcheva B; Monahan J; Zumstein-Mecker S; Choong PF; Dickinson I; Crowe P; Hemmings C; Desai J; Thomas DM; Lisztwan J
    Clin Cancer Res; 2011 Feb; 17(3):416-26. PubMed ID: 21159888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intimal sarcoma is the most frequent primary cardiac sarcoma: clinicopathologic and molecular retrospective analysis of 100 primary cardiac sarcomas.
    Neuville A; Collin F; Bruneval P; Parrens M; Thivolet F; Gomez-Brouchet A; Terrier P; de Montpreville VT; Le Gall F; Hostein I; Lagarde P; Chibon F; Coindre JM
    Am J Surg Pathol; 2014 Apr; 38(4):461-9. PubMed ID: 24625414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study.
    Koyama T; Shimizu T; Kojima Y; Sudo K; Okuma HS; Shimoi T; Ichikawa H; Kohsaka S; Sadachi R; Hirakawa A; Yoshida A; Ando RM; Ueno T; Yanagaki M; Matsui N; Nakamura K; Yamamoto N; Yonemori K
    Cancer Discov; 2023 Aug; 13(8):1814-1825. PubMed ID: 37369013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma.
    Ohnstad HO; Castro R; Sun J; Heintz KM; Vassilev LT; Bjerkehagen B; Kresse SH; Meza-Zepeda LA; Myklebost O
    Cancer; 2013 Mar; 119(5):1013-22. PubMed ID: 23165797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.
    Pishas KI; Neuhaus SJ; Clayer MT; Schreiber AW; Lawrence DM; Perugini M; Whitfield RJ; Farshid G; Manavis J; Chryssidis S; Mayo BJ; Haycox RC; Ho K; Brown MP; D'Andrea RJ; Evdokiou A; Thomas DM; Desai J; Callen DF; Neilsen PM
    Cancer Res; 2014 Feb; 74(3):921-31. PubMed ID: 24336067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?
    Le Guellec S; Chibon F; Ouali M; Perot G; Decouvelaere AV; Robin YM; Larousserie F; Terrier P; Coindre JM; Neuville A
    Am J Surg Pathol; 2014 Mar; 38(3):293-304. PubMed ID: 24525499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Automated brightfield dual-color in situ hybridization for detection of mouse double minute 2 gene amplification in sarcomas.
    Zhang W; McElhinny A; Nielsen A; Wang M; Miller M; Singh S; Rueger R; Rubin BP; Wang Z; Tubbs RR; Nagle RB; Roche P; Wu P; Pestic-Dragovich L
    Appl Immunohistochem Mol Morphol; 2011 Jan; 19(1):54-61. PubMed ID: 20881839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation.
    Kanoe H; Nakayama T; Murakami H; Hosaka T; Yamamoto H; Nakashima Y; Tsuboyama T; Nakamura T; Sasaki MS; Toguchida J
    Anticancer Res; 1998; 18(4A):2317-21. PubMed ID: 9703873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 Mutation and MDM2 amplification in human soft tissue sarcomas.
    Leach FS; Tokino T; Meltzer P; Burrell M; Oliner JD; Smith S; Hill DE; Sidransky D; Kinzler KW; Vogelstein B
    Cancer Res; 1993 May; 53(10 Suppl):2231-4. PubMed ID: 8387391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
    Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of heterozygosity at 12q14-15 often occurs in stage I soft tissue sarcomas and is associated with MDM2 amplification in tumors at various stages.
    Taubert H; Schuster K; Brinck U; Bartel F; Kappler M; Lautenschläger C; Bache M; Trump C; Schmidt H; Holzhausen HJ; Würl P; Schlott T
    Mod Pathol; 2003 Nov; 16(11):1109-16. PubMed ID: 14614050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary cardiac dedifferentiated liposarcoma with homologous and heterologous differentiation: a case report.
    He D; Chen M; Chen H; Liao D; Wang X; Zhang Z; Zhang H
    Int J Clin Exp Pathol; 2015; 8(8):9662-6. PubMed ID: 26464734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intimal sarcoma of the abdominal aorta with platelet-derived growth factor receptor α overexpression and amplification in mural invasive cells and pulmonary metastatic cells but not in intimal spreading cells.
    Tajima S; Takanashi Y; Takahashi T; Neyatani H
    Pathol Int; 2015 Aug; 65(8):426-31. PubMed ID: 25998154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytogenetic and molecular cytogenetic findings of intimal sarcoma.
    Zhang H; Macdonald WD; Erickson-Johnson M; Wang X; Jenkins RB; Oliveira AM
    Cancer Genet Cytogenet; 2007 Dec; 179(2):146-9. PubMed ID: 18036403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.